Physiology

Does gut hormone PYY3–36 decrease food intake in rodents?

  • A Corrigendum to this article was published on 22 September 2004

Abstract

Arising from: R. L. Batterham et al. Nature 418, 650–654 (2002); Batterham et al. reply

Batterham et al. report that the gut peptide hormone PYY3–36 decreases food intake and body-weight gain in rodents1, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al.1 cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3–36.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Lack of inhibitory effect of PYY3–36 on food intake in rodents.

References

  1. 1

    Batterham, R. L. et al. Nature 418, 650–654 (2002).

  2. 2

    Halford J. C. et al. Pharmacol. Biochem. Behav. 61, 159–168 (1998).

  3. 3

    Kanatani, A. et al. Endocrinology 141, 1011–1016 (2000).

  4. 4

    Allen, J. M. et al. Digestion 30, 255–262 (1984).

  5. 5

    Amersham Biosciences, RPNQ0085, Neuropeptide Y SPA binding assay (Y2).

  6. 6

    Halatchev, I. G. et al. Endocrinology 145, 2585–2590 (2004).

  7. 7

    Challis, B. G. et al. Biochem. Biophys. Res. Commun. 311, 915–919 (2003).

  8. 8

    Challis, B. G. et al. Proc. Natl Acad. Sci. USA 101, 4695–4700 (2004).

  9. 9

    Asakawa, A. et al. Gastroenterology 124, 1325–1336 (2003).

  10. 10

    Nordheim, U. & Hofbauer, K. G. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R138–R142 (2004).

Download references

Author information

Correspondence to M. Tschöp.

Ethics declarations

Competing interests

Several of the authors consult with, and have received financial support from, companies and institutions, including pharmaceutical firms, that may have active programmes relating to PYY3–36 of which we are not aware. Several of these companies have obesity-treatment development programmes and may therefore, from some perspectives, be considered competitors to companies pursuing PYY3–36.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tschöp, M., Castañeda, T., Joost, H. et al. Does gut hormone PYY3–36 decrease food intake in rodents?. Nature 430, 1–3 (2004). https://doi.org/10.1038/nature02665

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.